GlaxoSmithKline exercises option for BioMedica’s LentiVector non-exclusive patents

Oxford BioMedica plc, a gene and cell therapy group, has announced that GlaxoSmithKline PLC (GSK) has exercised an option to obtain a non-exclusive licence for two rare orphan disease indications under Oxford BioMedica’s LentiVector platform technology patents.

As Oxfor BioMedica said in its announcement on Wednesday, This follows an agreement signed between GSK and the Group in December 2013.

John Dawson, Chief Executive Officer of Oxford BioMedica, commented:

“This news further underlines the growing importance and demand for Oxford BioMedica’s leading technology and IP. We are pleased that GSK are using our unique lentiviral vector platform and hope they can rapidly advance the development of new treatments that will benefit patients suffering from rare orphan indications for whom current treatment options are limited.”